Posted on 23/09/2009 in Pharmaceutical Company Product News Grifols has published the preliminary results of a trial showing that the use of systematic practise of therapeutic plasmapheresis with human albumin in Alzheimer's patients works towards stabilising their condition.
The results point to the improvement of the cognitive status of the patients treated, as well as the mobilisation of amyloid beta in the blood of those who undergo therapeutic plasmapheresis with albumin.
However, it was also highlighted that the clinical trial must be completed before any improved cognitive development can be verified.
Doctor Boada, medical director of the Fundacio ACE and clinician head at the neurology service at the Vall d'Hebron Hospital in Barcelona, said: "It would be premature to draw definitive conclusions when we are only halfway through the trial, but the results published so far are positive and promising."
Last month, Grifols announced that its human anti-hepatitis B immunoglobulin drug Niuliva was launched in various countries in the EU.
Other news stories from 23/09/2009
Read more in the Zenopa News Archive
How this news is generated
|
